MCID: END075
MIFTS: 39

Endocervical Adenocarcinoma

Categories: Cancer diseases, Reproductive diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Endocervical Adenocarcinoma

MalaCards integrated aliases for Endocervical Adenocarcinoma:

Name: Endocervical Adenocarcinoma 11 14 71
Endocervical Carcinoma 71

Classifications:



External Ids:

Disease Ontology 11 DOID:0050940
UMLS 71 C1263762 C1299237

Summaries for Endocervical Adenocarcinoma

Disease Ontology: 11 An endocervical carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary: Endocervical Adenocarcinoma, also known as endocervical carcinoma, is related to adenocarcinoma and cervical adenocarcinoma. An important gene associated with Endocervical Adenocarcinoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Toll-like receptor signaling pathway and Endometrial cancer. The drugs Fludarabine and Aldesleukin have been mentioned in the context of this disorder. Affiliated tissues include t cells, cervix and lymph node, and related phenotypes are Decreased viability in pancreas lineage and Increased sensitivity to paclitaxel

Related Diseases for Endocervical Adenocarcinoma

Diseases related to Endocervical Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 297)
# Related Disease Score Top Affiliating Genes
1 adenocarcinoma 32.0 TP53 SMAD4 PTEN PIK3CA CDKN2A
2 cervical adenocarcinoma 31.6 TP53 MAPK8IP1 CDKN2A
3 adenocarcinoma in situ 31.5 U2AF1 TP53 MUC6 MAPK8IP1 CDKN2A
4 appendix adenocarcinoma 31.1 TP53 SMAD4
5 suppressor of tumorigenicity 3 31.1 TP53 CDKN2A
6 endometrial adenocarcinoma 30.9 TP53 PTEN PAX8 CDKN2A
7 mucinous adenocarcinoma 30.7 U2AF1 TP53 SMAD4 PIK3CA PAX8 MUC6
8 endometrioid ovary carcinoma 30.7 TP53 PTEN PIK3CA ARID1A
9 adenoma 30.6 TP53 SMAD4 PIK3CA MUC6 CDKN2A
10 squamous cell carcinoma 30.6 TP53 SMAD4 PTEN PIK3CA KMT2D FBXW7
11 ovarian mucinous neoplasm 30.6 U2AF1 PAX8 MUC6
12 peutz-jeghers syndrome 30.6 TP53 SMAD4 PTEN MUC6
13 cervical cancer 30.6 U2AF1 TP53 SMAD4 PTEN PIK3CA FBXW7
14 cholangiocarcinoma 30.6 TP53 SMAD4 PTEN PIK3CA CDKN2A
15 gastric adenocarcinoma 30.5 TP53 SMAD4 PTEN PIK3CA FBXW7 CDKN2A
16 cervical squamous cell carcinoma 30.5 TP53 SMAD4 PTEN PIK3CA KMT2D KMT2C
17 cervix endometriosis 30.4 MAPK8IP1 CDKN2A
18 clear cell adenocarcinoma 30.4 TP53 SMAD4 PAX8 ARID1A
19 female reproductive endometrioid cancer 30.3 TP53 PTEN PIK3CA PAX8 ARID1A
20 human papillomavirus infectious disease 30.3 TP53 PTEN PIK3CA ICOSLG CDKN2A
21 lynch syndrome 30.3 U2AF1 TP53 SMAD4 PTEN PIK3CA FBXW7
22 serous cystadenocarcinoma 30.2 TP53 PTEN PIK3CA PAX8 CDKN2A ARID1A
23 fanconi anemia, complementation group a 30.2 U2AF1 TP53 PTEN KMT2D CDKN2A ARID1A
24 ovary adenocarcinoma 30.1 U2AF1 TP53 SLC25A16 SIGLEC5 PTEN PIK3CA
25 rectum adenocarcinoma 30.1 U2AF1 TP53 SMAD4 SLC25A16 SIGLEC5 PIK3CA
26 adenoid cystic carcinoma 30.1 TP53 PTEN PIK3CA KMT2C FBXW7 EP300
27 endocervical carcinoma 30.0 U2AF1 TP53 SLC25A16 SIGLEC5 PTEN PIK3CA
28 renal cell carcinoma, nonpapillary 29.7 U2AF1 TP53 SLC25A16 SIGLEC5 PTEN PIK3CA
29 high-grade astrocytoma 10.5 TP53 PTEN
30 endometrial cancer 10.5
31 vulvar seborrheic keratosis 10.5 PTEN CDKN2A
32 lung oat cell carcinoma 10.4 TP53 PTEN PIK3CA
33 vaginal carcinosarcoma 10.4 TP53 PIK3CA FBXW7
34 ovarian clear cell adenocarcinoma 10.4 TP53 PIK3CA ARID1A
35 bartholin's gland adenoid cystic carcinoma 10.4 PIK3CA EP300 ARID1A
36 clear cell adenofibroma 10.4 PIK3CA ARID1A
37 lobular neoplasia 10.4 TP53 PTEN PIK3CA
38 b-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2) 10.4 TP53 CDKN2A
39 hypertrophy of breast 10.4 TP53 PTEN PIK3CA
40 esophagus verrucous carcinoma 10.4 TP53 PIK3CA CDKN2A
41 verrucous carcinoma 10.4 TP53 PIK3CA CDKN2A
42 breast lobular carcinoma 10.4 TP53 PTEN PIK3CA
43 penile benign neoplasm 10.4 TP53 PIK3CA CDKN2A
44 keratinizing squamous cell carcinoma 10.4 TP53 PIK3CA CDKN2A
45 endometriosis of ovary 10.4 PTEN PIK3CA ARID1A
46 adenofibroma 10.4 TP53 PAX8 ARID1A
47 cervical endometrioid adenocarcinoma 10.4 U2AF1 FBXW7
48 acanthoma 10.4 TP53 PIK3CA CDKN2A
49 colon adenoma 10.4 TP53 SMAD4 PIK3CA
50 idh-wildtype glioblastoma 10.4 TP53 PTEN CDKN2A

Graphical network of the top 20 diseases related to Endocervical Adenocarcinoma:



Diseases related to Endocervical Adenocarcinoma

Symptoms & Phenotypes for Endocervical Adenocarcinoma

GenomeRNAi Phenotypes related to Endocervical Adenocarcinoma according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability in pancreas lineage GR00235-A 9.16 ARID1A TP53
2 Increased sensitivity to paclitaxel GR00112-A-0 8.96 SMAD4
3 Increased CDKN1A mRNA expression GR00389-S-1 8.96 EP300 KMT2D
4 Increased BBC3 mRNA expression GR00389-S-3 8.62 EP300 KMT2D

MGI Mouse Phenotypes related to Endocervical Adenocarcinoma:

45 (show all 17)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.41 ARID1A CDKN2A DDX3X EP300 FAT1 FBXW7
2 nervous system MP:0003631 10.35 ARID1A CDKN2A DDX3X EP300 FAT1 FBXW7
3 growth/size/body region MP:0005378 10.34 ARID1A CDKN2A DDX3X EP300 FAT1 FBXW7
4 neoplasm MP:0002006 10.27 ARID1A CDKN2A EP300 FBXW7 KMT2D PIK3CA
5 muscle MP:0005369 10.22 ARID1A CDKN2A DDX3X EP300 FAT1 KMT2D
6 endocrine/exocrine gland MP:0005379 10.22 ARID1A CDKN2A DDX3X EP300 FBXW7 MAPK8IP1
7 normal MP:0002873 10.21 ARID1A DDX3X EP300 FBXW7 PAX8 PTEN
8 cellular MP:0005384 10.21 ARID1A CDKN2A DDX3X EP300 FBXW7 KMT2C
9 embryo MP:0005380 10.2 ARID1A CDKN2A DDX3X EP300 FBXW7 KMT2D
10 no phenotypic analysis MP:0003012 10.15 ARID1A CDKN2A FAT1 KMT2C PAX8 PIK3CA
11 cardiovascular system MP:0005385 10.13 ARID1A CDKN2A DDX3X EP300 FAT1 FBXW7
12 immune system MP:0005387 10.07 ARID1A CDKN2A EP300 FAT1 FBXW7 ICOSLG
13 digestive/alimentary MP:0005381 10.03 CDKN2A EP300 FBXW7 KMT2D PIK3CA PTEN
14 craniofacial MP:0005382 10.01 ARID1A EP300 FAT1 FBXW7 KMT2D PAX8
15 reproductive system MP:0005389 9.9 ARID1A CDKN2A DDX3X FBXW7 KMT2C MAPK8IP1
16 vision/eye MP:0005391 9.7 ARID1A CDKN2A EP300 FAT1 FBXW7 KMT2C
17 mortality/aging MP:0010768 9.5 ARID1A CDKN2A DDX3X EP300 FAT1 FBXW7

Drugs & Therapeutics for Endocervical Adenocarcinoma

Drugs for Endocervical Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 7)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fludarabine Approved Phase 1, Phase 2 75607-67-9, 21679-14-1 30751 657237
2
Aldesleukin Approved Phase 1, Phase 2 110942-02-4
3
Cyclophosphamide Approved, Investigational Phase 1, Phase 2 50-18-0, 6055-19-2 2907
4 Antiviral Agents Phase 1, Phase 2
5 Anti-Retroviral Agents Phase 1, Phase 2
6 Anti-Infective Agents Phase 1, Phase 2
7 Anti-HIV Agents Phase 1, Phase 2

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 A Feasibility Study of E7 TCR-T Cell Induction Therapy for Locoregionally Advanced HPV-Associated Cancers Not yet recruiting NCT05639972 Phase 1, Phase 2 Conditioning, E7 TCR-T cells, and aldesleukin
2 InAdvance: Surveillance, Prevention, and Interception in a Population at Risk For Cancer Not yet recruiting NCT05463796

Search NIH Clinical Center for Endocervical Adenocarcinoma

Genetic Tests for Endocervical Adenocarcinoma

Anatomical Context for Endocervical Adenocarcinoma

Organs/tissues related to Endocervical Adenocarcinoma:

MalaCards : T Cells, Cervix, Lymph Node, Uterus, Ovary, Smooth Muscle, Liver

Publications for Endocervical Adenocarcinoma

Articles related to Endocervical Adenocarcinoma:

(show top 50) (show all 556)
# Title Authors PMID Year
1
Distribution and incidence of atypical glandular lesions in cervical cytology focusing on the association with high-risk human papillomavirus subtypes. 62
36419751 2023
2
Using Silva pattern system to predict prognosis and plan treatment of invasive endocervical adenocarcinoma: a single-center retrospective analysis. 62
36460984 2022
3
The regulation role and diagnostic value of fibrinogen-like protein 1 revealed by pan-cancer analysis. 62
36345363 2022
4
Predicting prognosis according to the updated WHO classification in patients with endocervical adenocarcinoma treated with surgery and radiotherapy. 62
36047374 2022
5
Silva cumulative score and its relationship with prognosis in Endocervical adenocarcinoma. 62
36376880 2022
6
Adenocarcinoma of the uterine cervix, gastric-type (GAS): a review of the literature focused on pathology and multimodality imaging. 62
36334123 2022
7
Patterns and risk factors of recurrence in low-risk early-stage cervical adenocarcinoma treated with surgery alone: implications on risk group stratification. 62
36368708 2022
8
Benign stratified intraepithelial mucinous proliferation of the uterine cervix: Significance of a previously unreported potential mimic of SMILE. 62
35988376 2022
9
Diagnostic utility of ThinPrep Imaging System® for detecting atypical glandular cells in cervical smear samples. 62
36308412 2022
10
Gastric-type adenocarcinoma of the cervix: Clinical outcomes and genomic drivers. 62
36253302 2022
11
HPV-genotyping versus conventional cervical cytology as a screening method to detect dysplastic cervical epithelial changes. 62
36280748 2022
12
hsa-mir-133a-2 promotes the proliferation and invasion of cervical cancer cells by targeting the LAMB3-mediated PI3K/ATK pathway. 62
36305754 2022
13
Fine needle aspiration of pancreatic lesions focusing on secondary tumors with emphasis of metastatic breast cancer: A clinicopathological study with follow-up. 62
36281523 2022
14
Identification of a necroptosis-related prognostic gene signature associated with tumor immune microenvironment in cervical carcinoma and experimental verification. 62
36253777 2022
15
RNPS1 functions as an oncogenic splicing factor in cervical cancer cells. 62
36300671 2022
16
Transmembrane protein 121 as a novel inhibitor of cervical cancer metastasis. 62
35978921 2022
17
Neuroendocrine Carcinoma of the Uterine Cervix With Metastases to the Thyroid Gland: A Case Report and Clinical Pathological Review. 62
36312683 2022
18
Gene signatures, immune infiltration, and drug sensitivity based on a comprehensive analysis of m6a RNA methylation regulators in cervical cancer. 62
36058934 2022
19
Immune-related 3-lncRNA signature with prognostic connotation in a multi-cancer setting. 62
36180904 2022
20
Cytopathologic features of human papillomavirus-independent, gastric-type endocervical adenocarcinoma. 62
36128862 2022
21
Corrigendum to "False-Negative Pap Tests in Women with Biopsy-Proven Invasive Endocervical Adenocarcinoma/Adenocarcinoma In Situ: A Retrospective Analysis with Assessment of Inter-Observer Agreement" Journal of the American Society of Cytopathology 2021;11:3-12. 62
36114101 2022
22
Endocervical Adenocarcinoma: Comprehensive Histological Review and Re-classification of 123 Consecutive Cases According to the Updated World Health Organization Classification of Female Genital Tumors. 62
36039458 2022
23
Analysis of postoperative adjuvant therapy in 102 patients with gastric-type mucinous carcinoma of the uterine cervix: A multi-institutional study. 62
35354541 2022
24
Necroptosis-related lncRNA signature predicts prognosis and immune response for cervical squamous cell carcinoma and endocervical adenocarcinomas. 62
36175606 2022
25
Reproducibility of Morphologic Parameters of the International Endocervical Adenocarcinoma Criteria and Classification System and Correlation With Clinicopathologic Parameters: A Multi-Institutional Study. 62
34856570 2022
26
Independent validation of distinct clinicopathological features and prognosis among usual-type, mucinous-type and gastric-type endocervical adenocarcinoma categorised by new WHO classification (2020). 62
35346505 2022
27
Cytology, High-Risk Human Papillomavirus Testing and Serum CA19-9 in a Large Cohort of Patients with Invasive Cervical Adenocarcinomas: Correlation with a New Pathogenetic Classification. 62
36037112 2022
28
Clinical correlation of lymphovascular invasion and Silva pattern of invasion in early-stage endocervical adenocarcinoma: proposed binary Silva classification system. 62
35501168 2022
29
Ciliated/tubal-type in-situ and invasive endocervical adenocarcinoma: Report of three cases with limited follow-up and review of the literature. 62
35782103 2022
30
Characterizing the extracellular matrix transcriptome of cervical, endometrial, and uterine cancers. 62
35898192 2022
31
Establishment and validation of prognostic nomograms integrating histopathological features in patients with endocervical adenocarcinoma. 62
35999033 2022
32
A Snapshot of the Landscape of Endocervical Adenocarcinoma in Kenya: What Has HPV Got to Do with It? 62
36197776 2022
33
[Correlation of micropapillary patten, cribriform pattern and retraction clefting of endocervical adenocarcinoma with the Silva classification system and prognosis]. 62
35750638 2022
34
The splicing factor SF3B4 drives proliferation and invasion in cervical cancer by regulating SPAG5. 62
35853859 2022
35
[Revised German guidelines on the diagnosis and treatment of carcinoma of the uterine cervix-what's new for pathologists in 2021?] 62
35191993 2022
36
Membranous and nuclear staining of CLDN18 in HPV-independent and HPV-associated endocervical adenocarcinomas. 62
35861118 2022
37
Ovarian Metastasis by Gastric-type Endocervical Adenocarcinoma: A Clinicopathologic Description of 12 Cases. 62
34347666 2022
38
Construction of a four-mRNA prognostic signature with its ceRNA network in CESC. 62
35739227 2022
39
Squamous and Glandular Epithelial Tumors of the Cervix: A Pragmatical Review Emphasizing Emerging Issues in Classification, Diagnosis, and Staging. 62
35715166 2022
40
Clear Cell Carcinoma (CCC) of the Cervix Is a Human Papillomavirus (HPV)-independent Tumor Associated With Poor Outcome: A Comprehensive Analysis of 58 Cases. 62
34985047 2022
41
Pan‑cancer analyses reveal the regulation and clinical outcome association of PCLAF in human tumors. 62
35425993 2022
42
Comprehensive analysis of the exocytosis pathway genes in cervical cancer. 62
34995576 2022
43
ERBB3 methylation and immune infiltration in tumor microenvironment of cervical cancer. 62
35581263 2022
44
PTEN Loss and ARID1A Mutation in an HPV-positive Metastatic Adenocarcinoma Diagnosed Almost 18 yr After an Intact Cone Excision for Endocervical Adenocarcinoma In Situ. 62
34282106 2022
45
Tumoral Morphologic Features From Cervical Biopsies That Are Predictive of a Negligible Risk for Nodal Metastasis and Tumor Recurrence in Usual-type Cervical Adenocarcinomas: A Multi-institutional Study. 62
34753864 2022
46
Claudin-18 as a Promising Surrogate Marker for Endocervical Gastric-type Carcinoma. 62
34864774 2022
47
Endocervical adenocarcinoma in situ with ovarian metastases. 62
35379705 2022
48
Association of recurrent APOBEC3B alterations with the prognosis of gastric-type cervical adenocarcinoma. 62
35151492 2022
49
Grading of endocervical adenocarcinoma: a novel prognostic system based on tumor budding and cell cluster size. 62
34593968 2022
50
Gastric-phenotype Mucinous Carcinoma of the Fallopian Tube with Secondary Ovarian Involvement in a Woman with Peutz-Jeghers Syndrome: A Case Report. 62
35466733 2022

Variations for Endocervical Adenocarcinoma

Expression for Endocervical Adenocarcinoma

Search GEO for disease gene expression data for Endocervical Adenocarcinoma.

Pathways for Endocervical Adenocarcinoma

Pathways related to Endocervical Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 18)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.68 TP53 SMAD4 PIK3CA EP300 DDX3X
2
Show member pathways
12.55 TP53 SMAD4 PTEN PIK3CA CDKN2A
3 12.5 TP53 PTEN PIK3CA KMT2C CDKN2A
4
Show member pathways
12.3 TP53 SMAD4 PTEN PIK3CA
5
Show member pathways
12.08 TP53 SMAD4 EP300 CDKN2A
6
Show member pathways
11.94 CDKN2A PIK3CA PTEN TP53
7 11.91 TP53 SMAD4 PTEN EP300
8 11.73 TP53 PTEN PIK3CA
9 11.73 TP53 SMAD4 PTEN CDKN2A
10 11.68 TP53 SMAD4 PTEN PIK3CA
11 11.51 TP53 SMAD4 EP300 CDKN2A
12
Show member pathways
11.49 TP53 PTEN PIK3CA
13 11.43 TP53 EP300 CDKN2A
14 11.43 TP53 PTEN KMT2D KMT2C
15 11.3 TP53 PTEN EP300 CDKN2A
16 11.3 TP53 SMAD4 PTEN PIK3CA FAT1 CDKN2A
17 10.96 TP53 PTEN PIK3CA KMT2C FBXW7 EP300
18 10.8 SMAD4 PTEN EP300

GO Terms for Endocervical Adenocarcinoma

Biological processes related to Endocervical Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell growth GO:0030308 9.76 TP53 SMAD4 DDX3X CDKN2A
2 protein destabilization GO:0031648 9.65 FBXW7 EP300 CDKN2A
3 protein stabilization GO:0050821 9.61 TP53 PTEN FBXW7 EP300 CDKN2A
4 transcription initiation-coupled chromatin remodeling GO:0045815 9.1 TP53 EP300 ARID1A

Molecular functions related to Endocervical Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA binding GO:0003677 9.6 TP53 TCEA3 SMAD4 PAX8 KMT2D KMT2C

Sources for Endocervical Adenocarcinoma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....